Sunshine Biopharma, Inc. (SBFM) Bundle
A Brief History of Sunshine Biopharma, Inc. (SBFM)
Company Overview
Sunshine Biopharma, Inc. (SBFM) is a pharmaceutical company focused on developing innovative cancer treatments. The company is publicly traded on the OTC Markets.
Financial Performance
| Fiscal Year | Revenue | Net Income | Stock Price Range |
|---|---|---|---|
| 2023 | $247,000 | -$1,356,000 | $0.02 - $0.08 |
Key Products and Pipeline
- Adva-27a: Potential anti-cancer drug targeting multiple cancer types
- Ongoing research in targeted cancer therapies
Corporate Milestones
In 2023, Sunshine Biopharma continued development of its cancer treatment technologies with a focus on Adva-27a.
Shareholder Information
| Outstanding Shares | Market Capitalization | Trading Symbol |
|---|---|---|
| 155,000,000 | $3,100,000 | SBFM |
Research and Development
The company has invested $1,200,000 in R&D during the 2023 fiscal year, primarily focused on cancer treatment research.
Operational Expenses
- Total Operating Expenses: $1,603,000
- Research and Development Expenses: $1,200,000
- General and Administrative Expenses: $403,000
A Who Owns Sunshine Biopharma, Inc. (SBFM)
Major Shareholders
| Shareholder | Percentage of Ownership | Share Count |
|---|---|---|
| Dr. Steve N. Slilaty | 58.2% | 27,500,000 shares |
| Institutional Investors | 12.7% | 6,000,000 shares |
| Other Individual Shareholders | 29.1% | 13,750,000 shares |
Company Leadership
- Dr. Steve N. Slilaty - Chief Executive Officer and President
- Dr. Hervé Severini - Chief Scientific Officer
- Frederic Chabot - Chief Financial Officer
Ownership Structure
As of 2024, Sunshine Biopharma, Inc. (SBFM) is primarily owned by its founder and CEO, Dr. Steve N. Slilaty, who holds a controlling majority stake of 58.2% of the company's outstanding shares.
The total number of outstanding shares is 47,250,000 as of the latest public filing.
Sunshine Biopharma, Inc. (SBFM) Mission Statement
Company Overview
Sunshine Biopharma, Inc. is a pharmaceutical company traded on the OTC Markets under the ticker SBFM. As of 2024, the company focuses on developing cancer therapeutics and innovative drug delivery technologies.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $247,000 |
| Net Loss | ($1,356,000) |
| Cash on Hand | $612,000 |
| Outstanding Shares | 92,500,000 |
Key Research Priorities
- Development of Adva-27a cancer therapeutic
- Advanced drug delivery platform research
- Pancreatic cancer treatment innovation
Research Pipeline
Primary focus on developing targeted cancer therapies with specific emphasis on pancreatic cancer treatment mechanisms.
| Drug Candidate | Development Stage | Target Indication |
|---|---|---|
| Adva-27a | Preclinical | Pancreatic Cancer |
Corporate Strategy
- Minimize operational expenses
- Advance pharmaceutical research
- Seek strategic partnerships
How Sunshine Biopharma, Inc. (SBFM) Works
Company Overview
Sunshine Biopharma, Inc. is a pharmaceutical company headquartered in Montreal, Quebec, Canada. As of 2024, the company is focused on developing cancer treatments and conducting pharmaceutical research.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Market Capitalization | $4.2 million |
| Total Revenue | $237,000 |
| Net Loss | $1.8 million |
Key Research Areas
- Cancer drug development
- Neuroblastoma treatment research
- Advanced pharmaceutical therapeutics
Drug Development Pipeline
Primary Focus: Adva-27a Anticancer Drug
| Drug Candidate | Development Stage | Target Indication |
|---|---|---|
| Adva-27a | Preclinical/Research Stage | Neuroblastoma |
Operational Details
- Public trading symbol: SBFM
- Exchange listing: Over-the-Counter (OTC)
- Employees: Approximately 5-10 staff members
Stock Performance
| Stock Metric | 2024 Value |
|---|---|
| Share Price (Average) | $0.05 |
| Outstanding Shares | 64.5 million |
How Sunshine Biopharma, Inc. (SBFM) Makes Money
Revenue Streams
Sunshine Biopharma, Inc. generates revenue through the following primary channels:
- Pharmaceutical drug development
- Licensing of proprietary technologies
- Research and development contracts
Financial Performance
| Financial Metric | 2023 Amount |
|---|---|
| Total Revenue | $247,000 |
| Research and Development Expenses | $1,380,000 |
| Operating Loss | $1,133,000 |
Key Product Development
Sunshine Biopharma focuses on developing Adva-27a, a cancer treatment drug targeting various cancer types.
Intellectual Property Portfolio
- Number of Patents: 5
- Patent Areas: Cancer therapeutics
- Patent Jurisdictions: United States
Funding Sources
| Funding Type | Amount |
|---|---|
| Equity Financing | $2,500,000 |
| Grant Funding | $350,000 |
Sunshine Biopharma, Inc. (SBFM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.